Compare LGND & AAUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGND | AAUC |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | Canada |
| Employees | 68 | 2252 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | N/A | N/A |
| Metric | LGND | AAUC |
|---|---|---|
| Price | $227.24 | $31.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $247.29 | N/A |
| AVG Volume (30 Days) | 189.3K | ★ 241.7K |
| Earning Date | 05-07-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.25 | $94.92 |
| Revenue Next Year | $19.41 | $27.93 |
| P/E Ratio | $76.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $98.90 | $11.40 |
| 52 Week High | $238.31 | $32.08 |
| Indicator | LGND | AAUC |
|---|---|---|
| Relative Strength Index (RSI) | 62.26 | 65.10 |
| Support Level | $180.85 | $30.99 |
| Resistance Level | $227.92 | $32.08 |
| Average True Range (ATR) | 8.74 | 0.21 |
| MACD | 1.97 | 0.03 |
| Stochastic Oscillator | 74.64 | 76.58 |
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Allied Gold Corp is a company focused on gold mining activities in Africa. Allied has three mines and several development and exploration projects in Africa where it has operating experience. Operations are located in Cote d'Ivoire, Mali, and Ethiopia. The company expands and optimizes initiatives at existing operating mines, the development of new mines, the advancement of its exploration properties, and, targeting other consolidation opportunities with a focus on Africa.